Therapeutic efficacy of different-course azithromycin combined with NAC in elderly patients with COPD at stable stage
Objective To explore the clinical efficacy of different-course azithromycin combined with N-acetylcysteine(NAC)on elderly patients with COPD at stable stage.Methods A total of 114 elderly patients with COPD at stable stage admitted to our hospital from March 2020 to March 2023 were enrolled for this stud and randomly divided into 3 groups with 36 in each.The patients in group A,B and C were treated with azithromycin combined with NAC for 3,6 and 12 consecutive months,respectively.Then pulmonary function,clinical outcome,6-minute walk test(6-MWT),number of acute exacerbations,serum inflammatory factors and adverse effect rates were compared among the 3 groups.Results The overall efficacy rate was 92.11%in group B and 94.74%in group C,which was higher than that of 65.79%in group A(P<0.05),and no statistical difference was found between group B and C(P>0.05).A reduction in number of acute exacerbations,serum levels of interleukin(IL)-6,IL-8 and tumour necrosis factor-alpha(TNF-α),and an increase in inforced vital capacity(FVC),forced expiratory volume in first second(FEV1),FEV1/FVC,and 6MWT were observed in all patients after treatment(P<0.05),and both improvements were more notable in group B and C as compared to group A(P<0.05),whereas the above parameters yielded no statistical difference between group B and C(P>0.05).The rate of adverse reactions during treatment yielded no statistical difference among the 3 groups(P>0.05).Conclusion All three courses of azithromycin combined with NAC can effectively improve the lung function and inflammation response in elderly patients with COPD at stable stage.But the effect is better after medication for 6 and 12 months.
Chronic obstructive pulmonary diseaseStable stageAzithromycinN-acetylcysteineDifferent coursesPulmonary function
万方数据
维普
